Kunal Dhiman, Edith Cowan UniversityFollow
Veer Bala Gupta, Edith Cowan UniversityFollow
Victor L. Villemagne
Petra L. Graham
Ashley I. Bush
Christopher C. Rowe
Colin L. Masters
Eugene Hone, Edith Cowan UniversityFollow
Ralph N. Martins, Edith Cowan UniversityFollow
Ralph N Martins
Alzheimer's & Dementia
School of Medical and Health Sciences
National Health and Medical Research Council
NHMRC Number : APP1105784
This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation.
CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL).
CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P< .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition.
CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.
Dhiman, K. (2020). Utility of CSF biomarkers for the diagnosis, prognosis and assessment of cognitive decline in Alzheimer’s disease. https://ro.ecu.edu.au/theses/2284
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License